Essential Partners’s Prime Medicine PRME Stock Holding History

Essential Partners’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-27	Closed	-$100	–	2970
2026 Q2	$100	Sell	27 -981	-97%	-$3.26K	﹤0.01%	2745
2026 Q1	$3.51K	Buy	1,008 +787	+356%	+$3K	﹤0.01%	1753
2025 Q4	$767	Buy	221 +11	+5%	+$49	﹤0.01%	2111
2025 Q3	$1.16K	Hold	210	–	–	﹤0.01%	1977
2025 Q2	$519	Buy	+210	New	+$324	﹤0.01%	1691

Other funds holding PRME

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

MAM

Milestone Asset Management Pittsburgh, Pennsylvania $631M AUM 19.64% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return

Essential Partners's PRME Position: Q3 2026 in Review

Essential Partners sold out of Prime Medicine (PRME) in Q3 2026, closing a stake of 27 shares — an estimated $100 sold.

Essential Partners first reported a position in PRME in Q2 2025 and held it in 5 quarters. The position peaked at $3.51K in Q1 2026. 6 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

Essential Partners reported no remaining Prime Medicine position as of Q3 2026 after selling out during the quarter.
Essential Partners sold 27 Prime Medicine shares in Q3 2026, an estimated $100.
Essential Partners first reported a position in Prime Medicine in Q2 2025 and held it in 5 quarters.
Essential Partners's Prime Medicine position peaked at $3.51K in Q1 2026.
6 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.